Extensive-Stage Small Cell Lung CancerPhase 1/2NCT07328490
Bispecific T-Cell Engager Tarlatamab and TROP2 Targeted Antibody Drug Conjugate Sacituzumab Govitecan in Previously Treated Extensive-Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancer
A Phase 1/2 study testing Tarlatamab and Sacituzumab Govitecan in people with Extensive-Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Carcinoma, run by National Cancer Institute (NCI) at 1 site in United States.
Trial summary
Background: Small-cell lung cancer (SCLC) is the most deadly form of lung cancer. It kills at least 250,000 worldwide each year. Extra-pulmonary neuroendocrine cancer (EP-NEC) is a similar type of cancer that develops anywhere other than the lungs. EP-NEC is also very aggressive. Read more about this study
- Who is it for?
- Ages 18 to 120 years
- Conditions the study is for
- Extensive-Stage Small Cell Lung Cancer, Extrapulmonary Neuroendocrine Carcinoma, Small Cell Carcinoma
- What is being tested?
- Tarlatamab and Sacituzumab Govitecan
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 0 participants
- Where
- 1 siteUnited States
- Study dates
- 25 Apr 2026to 25 Apr 2026
- Phase
- Phase 1/2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 120 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Must have histologically or cytologically confirmed SCLC or EP-NEC meeting the criteria below:
- SCLC that has progressed or recurred after a combination of platinum-based regimen and immunotherapy. Participants may be eligible after treatment with chemo or immunotherapy alone if they were intolerant to one of the components. Participants with previously locally advanced SCLC who have completed definitive chemoradiation therapy, with or without surgical resection, and subsequently experienced disease progression or recurrence, are also eligible. OR
- EP-NEC that has progressed or recurred after at least one prior chemotherapy.
- Must have measurable disease, per RECIST 1.1
- Age >=18 years.
- Eastern Cooperative Oncology Group (ECOG) performance status <=2.
Show all 36Show fewer
- Must have adequate organ and marrow function as defined below:
- System/Laboratory Value
- Hematological
- Hemoglobin/>=9 g/dL(a)
- Absolute neutrophil count/>= 1,500/mcL
- Platelets/>= 100,000/mcL
- System/Laboratory Value
- Hepatic
- Total bilirubin/within normal institutional limits
- AST (SGOT) and ALT (SGPT) <= 2.5 X institutional ULN (<=5 X ULN for participants with liver metastases)
- Renal
- -Creatinine/ within normal institutional limits
- OR
- -Calculated (b) creatinine clearance (GFR can also be used in place of creatinine or CrCl)/>=60 mL/min for participant with creatinine levels above institutional normal
- OR
- Coagulation
- Prothrombin time (PT) <=1.5 x ULN unless participant is receiving anticoagulant therapy if PT or PTT is within therapeutic range of intended use of anticoagulants
- Partial thromboplastin time (PTT) <=1.5 x ULN unless participant is receiving anticoagulant therapy if PT or PTT is within therapeutic range of intended use of anticoagulants
- ALT (SGPT)=alanine aminotransferase (serum glutamic pyruvic transaminase);
- AST (SGOT)=aspartate aminotransferase (serum glutamic oxaloacetic transaminase);
- GFR=glomerular filtration rate; ULN=upper limit of normal.
- Criteria must be met without erythropoietin dependency and without packed red blood cell (pRBC) transfusion within last 2 weeks.
- Creatinine clearance (CrCl) should be calculated per institutional standard.
- Individuals with neurologically stable brain metastases defined as asymptomatic metastasis, or treated metastasis having no evidence of progression or hemorrhage for at least 1 week after treatment (including brain radiotherapy) may be included. Individuals must be off any systemic corticosteroids for the treatment of brain metastases for at least 7 days prior to study drug initiation.
- Individuals with human immunodeficiency virus (HIV) must be on effective antiretroviral therapy with undetectable viral load at screening.
- Individuals with evidence of chronic hepatitis B virus (HBV) infection must have undetectable HBV viral load at screening.
- Individuals with a history of hepatitis C virus (HCV) infection must have been treated and cured. Individuals with active HCV infection who are currently on treatment are eligible if they have an undetectable HCV viral load at screening.
- Must agree to use an effective method of contraception (barrier, hormonal, intrauterine device [IUD], surgical sterilization, abstinence) during study treatment and for 3 months thereafter for males or 6 months for women of childbearing potential (WOCBP).
- Willingness to discontinue nursing during study treatment and for 2 months after the last dose of study treatment.
- Ability to understand and the willingness to sign a written informed consent document.
Who cannot join
- Receiving any other investigational agents or concurrent systemic anti-cancer therapies. Any previous non-investigational treatment must be completed at least 2 weeks prior to study drug initiation.
- Prior exposure to tarlatamab or other DLL3-targeting agents/T-cell engagers (TCE).
- Requiring radiation therapy during study treatment. Radiation therapy may be allowed if needed for palliative/symptom control (e.g., bone metastasis) but must be completed at least 7 days before study drug initiation.
- Severe and unresolved active autoimmune inflammatory conditions.
- Pregnant women, breastfeeding women, and women planning to become pregnant or donate eggs should not take part in this study.
- Requiring immunosuppressive agents with the exception of those required by protocol, treatment for adverse events, Central Nervous System (CNS) metastases corticosteroid replacement therapy.
Show all 11Show fewer
- Require live and live-attenuated vaccines during study treatment with tarlatamab or within 4 weeks of first dose of tarlatamab. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, chicken pox, yellow fever, rabies, Bacillus Calmette-Guerin (BCG), and typhoid (oral) vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed. However, intranasal influenza vaccines (e.g., Flu-Mist) are live attenuated vaccines and are not allowed.
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to study drugs or other agents used in study.
- Requiring treatment with inhibitors or inducers of UGT1A1 during the planned period of study treatment.
- QTc >= 470 msec or any conditions or factors that may increase the risk of QTc prolongation.
- Uncontrolled intercurrent illness, evaluated by medical history and physical exam which would potentially increase risk to the participant.
Trial locations and contacts
1 site in 1 country.
United States1 site
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892
About this study
Official title: A Phase I/II Study to Assess the Safety and Antitumor Activity of Bispecific T-cell Engager Tarlatamab and TROP2 Targeted Antibody Drug Conjugate Sacituzumab Govitecan in Previously Treated Extensive-Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancer
Background:
Small-cell lung cancer (SCLC) is the most deadly form of lung cancer. It kills at least 250,000 worldwide each year. Extra-pulmonary neuroendocrine cancer (EP-NEC) is a similar type of cancer that develops anywhere other than the lungs. EP-NEC is also very aggressive. Better treatments are needed for these cancers.
Read more
Objective:
To test 2 drugs (tarlatamab combined with sacituzumab govitecan [SG]) in people with SCLC or EP-NEC.
Eligibility:
People aged 18 years and older with SCLC or EP-NEC that either did not respond to or returned after treatment.
Design:
Participants will be screened with a physical exam, blood tests, heart function testing, and imaging scans.
Both study drugs are given intravenously (through a needle in the arm). Participants will receive a small starter dose of tarlatamab (1 mg) 2 weeks before beginning regular treatment, followed by the full dose (10 mg) one week later. Treatment then follows a repeating 4-week cycle: tarlatamab (10 mg) on days 1 and 15, and sacituzumab govitecan (7.5 or 10 mg/kg) on days 1 and 8. Treatment continues for up to 2 years, unless the cancer worsens, the participant passes away, or side effects become too severe.
Participants will have regular check-ups including physical exams, blood tests, and imaging scans to monitor safety and treatment response. Blood and tumor samples will be collected for research purposes.
After stopping treatment, participants will return for a safety check at 30 days, then be contacted every 3 months to check on their health and survival. Those who stop treatment for reasons other than cancer progression will continue CT scans every 8 weeks until their disease progresses.
Read the detailed description
Background:
- Small-cell lung cancer (SCLC) is the most fatal and metastatic form of lung cancer which kills at least 250,000 people globally each year including more than 30,000 in the United States. SCLC constitutes approximately 14% of all lung cancers.
- SCLC consists of tumor cells with neuroendocrine (NE) and non-neuroendocrine (non-NE) features. SCLC subtypes exhibit distinct therapeutic vulnerabilities. Immunogenic plasticity and Notch signaling of non-NE SCLC underlie their responses to immune checkpoint blockade. NE SCLC is characterized by replication stress, rendering them susceptible to deoxyribonucleic acid (DNA) repair-targeted agents.
- The inhibitory Notch delta-like ligand 3 (DLL3) is aberrantly expressed on the surface of up to 85% of SCLC, mostly NE cells and minimally expressed in normal tissues, making it a compelling therapeutic target for NE SCLC. Trophoblast cell-surface antigen 2 (TROP2) is a transmembrane glycoprotein aberrantly expressed in SCLC during its progression from NE to the non-NE cell state, making it a compelling therapeutic target of non-NE SCLC.
- Tarlatamab is a bispecific T cell engager (BiTE) molecule which binds DLL3 on cancer cells and cluster of differentiation 3 (CD3) on T cells leading to T cell-mediated tumor lysis. Sacituzumab govitecan (SG) is an antibody drug conjugate (ADC) carrying a topoisomerase 1 (TOP1) inhibitor SN-38 payload to cancer cells expressing TROP2.
- Extrapulmonary neuroendocrine cancers (EP-NEC) are rare and aggressive orphan cancers that share morphological and transcriptomic similarities and potentially therapeutic vulnerabilities with SCLC, with no standard treatments at relapse.
- In the current study, combination therapies targeting DLL3 and TROP2, using a combination of tarlatamab and sacituzumab govitecan will be evaluated as potential drivers of durable response in SCLC and EP-NEC.
Objectives:
Phase I:
-To determine the maximum tolerated dose (MTD) of bispecific T-cell engager tarlatamab and TROP2 targeted antibody drug conjugate sacituzumab govitecan in participants with previously treated relapsed SCLC or EP-NEC.
Phase II:
-To determine the clinical benefit in terms of objective response rates (ORR) in participants with previously treated relapsed SCLC or EP-NEC.
Eligibility:
->=18 years.
- Histologically or cytologically confirmed SCLC or EP-NEC that has progressed or recurred after at least one previous platinum-based regimen and immunotherapy.
- Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less.
Design:
- This is a Phase I/II, open label clinical trial aimed at identifying the MTD of Sacituzumab govitecan in combination with tarlatamab and assessing the efficacy with respect to objective response rate in recurrent SCLC and EP-NEC.
- Participants will receive a step dose of 1mg tarlatamab 14 days prior to the first cycle followed by a full dose (10mg) starting a week later. Thereafter, tarlatamab will be administered on days 1 and 15 and sacituzumab govitecan (7.5 or 10 mg/Kg) will be administered on days 1 and 8 of every 4-week cycle. Treatment will be administered for up to 2 years or until disease progression/death or development of intolerable side effects (whichever occurs first).
- During treatment, participants will have clinical assessments, laboratory evaluations, and imaging studies for safety and response assessment. Blood and tumor samples will be collected for correlative studies at various timepoints.
- Participants will be followed for survival every 3 months following objective disease progression.
- Conditions
- Extensive-Stage Small Cell Lung Cancer, Extrapulmonary Neuroendocrine Carcinoma, Small Cell Carcinoma
- Being tested
- Tarlatamab, Sacituzumab Govitecan
- Keywords
- Tarlatamab, Sacituzumab Govitecan, Bispecific T-cell Engager, Immunotherapy, Antibody Drug Conjugate, Targeted Therapy
- Medical subject headings
- Small Cell Lung Carcinoma, Carcinoma, Small Cell
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
TarlatamabDrug
For both Phase I and Phase II, participants will receive a step dose of 1 mg of Tarlatamab (IV) followed by a full dose of 10 mg starting 7 days later (i.e., step dosing phase). Cycle 1 will begin following the Tarlatamab step-dosing (i.e., 14 days after the first dose and 7 days after the second dose of Tarlatamab alone) with participants receiving a combination of Tarlatamab (full dose) and Sacituzumab Govitecan (IV 7.5 or 10 mg/Kg) on day 1, SG alone on day 8 and Tarlatamab alone on day 15 of every cycle (4-week cycles) for up to 2 years or until disease progression/death, development of intolerable side effects.
Sacituzumab GovitecanDrug
For both Phase I and Phase II, participants will receive a step dose of 1 mg of Tarlatamab (IV) followed by a full dose of 10 mg starting 7 days later (i.e., step dosing phase). Cycle 1 will begin following the Tarlatamab step-dosing (i.e., 14 days after the first dose and 7 days after the second dose of Tarlatamab alone) with participants receiving a combination of Tarlatamab (full dose) and Sacituzumab Govitecan (IV 7.5 or 10 mg/Kg) on day 1, SG alone on day 8 and Tarlatamab alone on day 15 of every cycle (4-week cycles) for up to 2 years or until disease progression/death, development of intolerable side effects.
| Study group | Role | What they receive |
|---|---|---|
| 1/ Phase I | Experimental | Dose escalated Tarlatamab and Sacituzumab Govitecan Receives: Drug: Tarlatamab; Drug: Sacituzumab Govitecan |
| 2/ Phase II | Experimental | Maximum tolerated dose (MTD) Tarlatamab and Sacituzumab Govitecan Receives: Drug: Tarlatamab; Drug: Sacituzumab Govitecan |
What is being measured
The primary outcome is the main question the study is designed to answer.
Phase I: Maximum Tolerated Dose (MTD)
The toxicities identified at each dose level will be reported, by dose level, type, and grade.
Measured: Dose Limiting Toxicity (DLT) period (C1D1 through C1D28)
Phase II: Objective Response Rate (ORR)
In each of the two main cohorts, the fraction of participants who experience a partial response (PR) or complete response (CR) will be reported along with a 95% confidence interval.
Measured: Until disease progression
Secondary outcomes (3)
Safety
Toxicities identified at each dose level will be reported, by dose level, type, and grade.
Measured: Study duration
Overall survival (OS)
OS will be calculated from the on-study date until date of death, or 6 months after the last study participant goes off-treatment, whichever comes earlier.
Measured: Until death or study is stopped
Duration of response (DOR) and Progression free survival (PFS)
Duration of response will be calculated by the Kaplan-Meier method, starting at date response was identified until progression or the response is declared to have ended, if the participants have a PR or CR.PFS will be calculated from on-study date until date of progression or death without progression, using the Kaplan-Meier method.
Measured: Until disease progression
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Jan 2026
- Study start25 Apr 2026
- Primary completion25 Apr 2026
- Study completion25 Apr 2026
Why it stopped: Study drug supplier withdrew support; no participants were enrolled.
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Extensive-Stage Small Cell Lung CancerStudies of the same condition, open and under way.
- More trials run by National Cancer Institute (NCI)The sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1/2
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Sequential
- Masking
- None (open label)
- Enrolment
- 0 participants (actual)
Sponsor and investigators
- Lead sponsor
- National Cancer Institute (NCI)
- Sponsor type
- US National Institutes of Health
- Responsible party
- Sponsor
- Investigators
- Anish Thomas, M.D., Principal investigator, National Cancer Institute (NCI)
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07328490
- Sponsor's protocol ID
- 10001942
- Other IDs
- 001942-C
- Status last verified
- Apr 2026
- First submitted
- 8 Jan 2026
- Last updated
- 28 Apr 2026
- Results posted
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Yes: All IPD recorded in the medical record will be shared with intramural investigators upon request. This study will comply with the NIH Data Management and Sharing (DMS) Policy, which applies to all new and ongoing NIH-funded research in the IRP, as of January 25, 2023, that is associated with a ZIA, with a clinical protocol that undergoes scientific review.
Study at a glance
From the registry record, last updated by the sponsor on 28 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase I/II Study to Assess the Safety and Antitumor Activity of Bispecific T-cell Engager Tarlatamab and TROP2 Targeted Antibody Drug Conjugate Sacituzumab Govitecan in Previously Treated Extensive-Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancer
- ClinicalTrials.gov ID
- NCT07328490
- Acronym / sponsor ID
- 10001942
- Conditions
- Extensive-Stage Small Cell Lung Cancer, Extrapulmonary Neuroendocrine Carcinoma, Small Cell Carcinoma
- Keywords
- Tarlatamab, Sacituzumab Govitecan, Bispecific T-cell Engager, Immunotherapy, Antibody Drug Conjugate, Targeted Therapy
- Phase
- Phase 1/2
- Study type
- Interventional
- Recruitment status
- WithdrawnReason stopped: Study drug supplier withdrew support; no participants were enrolled.
- Enrolment
- 0 participants (actual)
- Lead sponsor
- National Cancer Institute (NCI)US National Institutes of Health
- Study start
- 25 Apr 2026 (actual)
- Primary completion
- 25 Apr 2026 (actual)
- Study completion
- 25 Apr 2026 (actual)
- First posted
- 9 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Background:
Small-cell lung cancer (SCLC) is the most deadly form of lung cancer. It kills at least 250,000 worldwide each year. Extra-pulmonary neuroendocrine cancer (EP-NEC) is a similar type of cancer that develops anywhere other than the lungs. EP-NEC is also very aggressive. Better treatments are needed for these cancers.
Objective:
To test 2 drugs (tarlatamab combined with sacituzumab govitecan [SG]) in people with SCLC or EP-NEC.
Eligibility:
People aged 18 years and older with SCLC or EP-NEC that either did not respond to or returned after treatment.
Design:
Participants will be screened with a physical exam, blood tests, heart function testing, and imaging scans.
Both study drugs are given intravenously (through a needle in the arm). Participants will receive a small starter dose of tarlatamab (1 mg) 2 weeks before beginning regular treatment, followed by the full dose (10 mg) one week later. Treatment then follows a repeating 4-week cycle: tarlatamab (10 mg) on days 1 and 15, and sacituzumab govitecan (7.5 or 10 mg/kg) on days 1 and 8. Treatment continues for up to 2 years, unless the cancer worsens, the participant passes away, or side effects become too severe.
Participants will have regular check-ups including physical exams, blood tests, and imaging scans to monitor safety and treatment response. Blood and tumor samples will be collected for research purposes.
After stopping treatment, participants will return for a safety check at 30 days, then be contacted every 3 months to check on their health and survival. Those who stop treatment for reasons other than cancer progression will continue CT scans every 8 weeks until their disease progresses.
Detailed description
Background:
- Small-cell lung cancer (SCLC) is the most fatal and metastatic form of lung cancer which kills at least 250,000 people globally each year including more than 30,000 in the United States. SCLC constitutes approximately 14% of all lung cancers.
- SCLC consists of tumor cells with neuroendocrine (NE) and non-neuroendocrine (non-NE) features. SCLC subtypes exhibit distinct therapeutic vulnerabilities. Immunogenic plasticity and Notch signaling of non-NE SCLC underlie their responses to immune checkpoint blockade. NE SCLC is characterized by replication stress, rendering them susceptible to deoxyribonucleic acid (DNA) repair-targeted agents.
- The inhibitory Notch delta-like ligand 3 (DLL3) is aberrantly expressed on the surface of up to 85% of SCLC, mostly NE cells and minimally expressed in normal tissues, making it a compelling therapeutic target for NE SCLC. Trophoblast cell-surface antigen 2 (TROP2) is a transmembrane glycoprotein aberrantly expressed in SCLC during its progression from NE to the non-NE cell state, making it a compelling therapeutic target of non-NE SCLC.
- Tarlatamab is a bispecific T cell engager (BiTE) molecule which binds DLL3 on cancer cells and cluster of differentiation 3 (CD3) on T cells leading to T cell-mediated tumor lysis. Sacituzumab govitecan (SG) is an antibody drug conjugate (ADC) carrying a topoisomerase 1 (TOP1) inhibitor SN-38 payload to cancer cells expressing TROP2.
- Extrapulmonary neuroendocrine cancers (EP-NEC) are rare and aggressive orphan cancers that share morphological and transcriptomic similarities and potentially therapeutic vulnerabilities with SCLC, with no standard treatments at relapse.
- In the current study, combination therapies targeting DLL3 and TROP2, using a combination of tarlatamab and sacituzumab govitecan will be evaluated as potential drivers of durable response in SCLC and EP-NEC.
Objectives:
Phase I:
-To determine the maximum tolerated dose (MTD) of bispecific T-cell engager tarlatamab and TROP2 targeted antibody drug conjugate sacituzumab govitecan in participants with previously treated relapsed SCLC or EP-NEC.
Phase II:
-To determine the clinical benefit in terms of objective response rates (ORR) in participants with previously treated relapsed SCLC or EP-NEC.
Eligibility:
->=18 years.
- Histologically or cytologically confirmed SCLC or EP-NEC that has progressed or recurred after at least one previous platinum-based regimen and immunotherapy.
- Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less.
Design:
- This is a Phase I/II, open label clinical trial aimed at identifying the MTD of Sacituzumab govitecan in combination with tarlatamab and assessing the efficacy with respect to objective response rate in recurrent SCLC and EP-NEC.
- Participants will receive a step dose of 1mg tarlatamab 14 days prior to the first cycle followed by a full dose (10mg) starting a week later. Thereafter, tarlatamab will be administered on days 1 and 15 and sacituzumab govitecan (7.5 or 10 mg/Kg) will be administered on days 1 and 8 of every 4-week cycle. Treatment will be administered for up to 2 years or until disease progression/death or development of intolerable side effects (whichever occurs first).
- During treatment, participants will have clinical assessments, laboratory evaluations, and imaging studies for safety and response assessment. Blood and tumor samples will be collected for correlative studies at various timepoints.
- Participants will be followed for survival every 3 months following objective disease progression.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Sequential
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| 1/ Phase I | Experimental | Drug: Tarlatamab, Drug: Sacituzumab GovitecanDose escalated Tarlatamab and Sacituzumab Govitecan |
| 2/ Phase II | Experimental | Drug: Tarlatamab, Drug: Sacituzumab GovitecanMaximum tolerated dose (MTD) Tarlatamab and Sacituzumab Govitecan |
Who may qualify
- Ages
- 18 to 120 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (36 listed)
- Must have histologically or cytologically confirmed SCLC or EP-NEC meeting the criteria below:
- Must have measurable disease, per RECIST 1.1
- Age >=18 years.
- Eastern Cooperative Oncology Group (ECOG) performance status <=2.
- Must have adequate organ and marrow function as defined below:
Key exclusion criteria (11 listed)
- Receiving any other investigational agents or concurrent systemic anti-cancer therapies. Any previous non-investigational treatment must be completed at least 2 weeks prior to study drug initiation.
- Prior exposure to tarlatamab or other DLL3-targeting agents/T-cell engagers (TCE).
- Requiring radiation therapy during study treatment. Radiation therapy may be allowed if needed for palliative/symptom control (e.g., bone metastasis) but must be completed at least 7 days before study drug initiation.
- Severe and unresolved active autoimmune inflammatory conditions.
- Pregnant women, breastfeeding women, and women planning to become pregnant or donate eggs should not take part in this study.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| TarlatamabFor both Phase I and Phase II, participants will receive a step dose of 1 mg of Tarlatamab (IV) followed by a full dose of 10 mg starting 7 days later (i.e., step dosing phase). Cycle 1 will begin following the Tarlatamab step-dosing (i.e., 14 days after the first dose and 7 days after the second dose of Tarlatamab alone) with participants receiving a combination of Tarlatamab (full dose) and Sacituzumab Govitecan (IV 7.5 or 10 mg/Kg) on day 1, SG alone on day 8 and Tarlatamab alone on day 15 of every cycle (4-week cycles) for up to 2 years or until disease progression/death, development of intolerable side effects. | Drug | 1/ Phase I, 2/ Phase II |
| Sacituzumab GovitecanFor both Phase I and Phase II, participants will receive a step dose of 1 mg of Tarlatamab (IV) followed by a full dose of 10 mg starting 7 days later (i.e., step dosing phase). Cycle 1 will begin following the Tarlatamab step-dosing (i.e., 14 days after the first dose and 7 days after the second dose of Tarlatamab alone) with participants receiving a combination of Tarlatamab (full dose) and Sacituzumab Govitecan (IV 7.5 or 10 mg/Kg) on day 1, SG alone on day 8 and Tarlatamab alone on day 15 of every cycle (4-week cycles) for up to 2 years or until disease progression/death, development of intolerable side effects. | Drug | 1/ Phase I, 2/ Phase II |
Primary outcome
Phase I: Maximum Tolerated Dose (MTD)
Time frame: Dose Limiting Toxicity (DLT) period (C1D1 through C1D28)
The toxicities identified at each dose level will be reported, by dose level, type, and grade.
Phase II: Objective Response Rate (ORR)
Time frame: Until disease progression
In each of the two main cohorts, the fraction of participants who experience a partial response (PR) or complete response (CR) will be reported along with a 95% confidence interval.
3 secondary outcomes
Safety
Time frame: Study duration
Overall survival (OS)
Time frame: Until death or study is stopped
Duration of response (DOR) and Progression free survival (PFS)
Time frame: Until disease progression
Results and safety
The study was withdrawn before enrolling participants, so there are no results.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Apr 2026.
- NIH Clinical Center Detailed Web PageLink provided by the sponsor.
- Individual participant dataSharing planned: Yes. All IPD recorded in the medical record will be shared with intramural investigators upon request. This study will comply with the NIH Data Management and Sharing (DMS) Policy, which applies to all new and ongoing NIH-funded research in the IRP, as of January 25, 2023, that is associated with a ZIA, with a clinical protocol that undergoes scientific review.
Related trials for Extensive-Stage Small Cell Lung Cancer
Active, not recruitingPhase 3
Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab
Extensive-Stage Small-Cell Lung Cancer, Small-Cell Lung Cancer
RecruitingPhase 2
A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC
Extensive-stage Small-cell Lung Cancer
Active, not recruitingPhase 2
Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy
Extensive-stage Small-cell Lung Cancer, Small-cell Lung Cancer
RecruitingPhase 2
MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer
Small Cell Lung Cancer, SCLC
Not yet recruitingPhase 2
Low-Dose Radiotherapy Plus Adebrelimab and Chemotherapy for Extensive-Stage Small Cell Lung Cancer
Small Cell Lung Cancer (SCLC), SCLC, Extensive Stage
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Anish Thomas, M.D. principal investigator
National Cancer Institute (NCI)
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1/2 study testing Tarlatamab and Sacituzumab Govitecan in people with Extensive-Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Carcinoma, run by National Cancer Institute (NCI) at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 36 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: withdrawn, as of the sponsor's last update on 28 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this combined phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study was withdrawn before enrolling participants, so there are no results.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Phase I: Maximum Tolerated Dose (MTD) (time frame: Dose Limiting Toxicity (DLT) period (C1D1 through C1D28)). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Apr 2026.